explore -WSS

explore

author：Wikipedia 2025-10-01 20:14:37 - browse：93

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a polarizing potential treatment for ALS on Wednesday, concluding that the medicine’s messy supporting data did not meet the standard for approval.

After a day-long meeting that included impassioned testimony from ALS patients, the agency’s expert advisers voted 17-1 with one abstention that the case for NurOwn, a treatment from BrainStorm Cell Therapeutics, was based too heavily on convoluted clinical trial results and compelling but unreliable anecdotal evidence.

“Patients and families need hope, but providing false hope can be ethically problematic,” said panelist Lisa Lee, a bioethicist at Virginia Tech. “False hope is provided when the probability of a positive outcome is overestimated, and I think that seems to be the case here.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Boston competes with Raleigh

WSS

Brazil's Jair Bolsonaro is barred from running for office until 2030

Eating disorder hotline's move to chatbot carried cost for volunteers

Ukrainian soldiers say they owe lives to US

Here's how to stay safe from wildfire smoke amid reduced air quality

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Merck CEO won’t testify in Senate, citing no expertise in drug prices

hotspot

explore

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Tuskegee Airman Raymond Cassagnol dies at 102

Virginia high school admissions case could be legal follow

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

Dobbs anniversary: the lost opportunity of abortion as health care

White House pharmacy plagued with problems, investigation finds

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

The high cost of giving birth even with insurance

Biogen walks away from Aduhelm, years after polarizing approval

focus

Medical experts exlpore how to eliminate bias in clinical algorithms

Why do we get seasonal allergies?

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Synthetic human embryos? Researchers say term is overblown

Pancreatic cancer early detection could be helped by AI

Supreme Court rules employers must be more accommodating of religious observance

explore

knowledge

hotspot

Wikipedia